336 related articles for article (PubMed ID: 20679887)
21. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant chemotherapy in non-small cell lung cancer.
Le Chevalier T
Semin Oncol; 1998 Aug; 25(4 Suppl 9):62-5. PubMed ID: 9728587
[TBL] [Abstract][Full Text] [Related]
23. Advances in our understanding of postoperative adjuvant chemotherapy in resectable non-small-cell lung cancer.
Hotta K; Matsuo K; Kiura K; Ueoka H; Tanimoto M
Curr Opin Oncol; 2006 Mar; 18(2):144-50. PubMed ID: 16462183
[TBL] [Abstract][Full Text] [Related]
24. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature.
Alam N; Shepherd FA; Winton T; Graham B; Johnson D; Livingston R; Rigas J; Whitehead M; Ding K; Seymour L
Lung Cancer; 2005 Mar; 47(3):385-94. PubMed ID: 15713522
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant chemotherapy for surgically resected non-small cell lung cancer.
Heon S; Johnson BE
J Thorac Cardiovasc Surg; 2012 Sep; 144(3):S39-42. PubMed ID: 22502967
[TBL] [Abstract][Full Text] [Related]
26. [Adjuvant chemotherapy for resectable non-small cell lung cancer (NSCLC)].
Nakajima E; Katou H
Kyobu Geka; 2008 Jan; 61(1):4-8. PubMed ID: 18186265
[TBL] [Abstract][Full Text] [Related]
27. The future of adjuvant chemotherapy for resected non-small cell lung cancer.
Vansteenkiste JF; Schildermans RH
Expert Rev Anticancer Ther; 2005 Feb; 5(1):165-75. PubMed ID: 15757448
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant chemotherapy for non-small cell lung cancer: a New Zealand perspective.
Sasidharan R; Gibbs D; Sullivan R; Simpson A; Perez D; Christmas T; McKeage M
N Z Med J; 2006 Nov; 119(1245):U2310. PubMed ID: 17146485
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant chemotherapy for non-small cell lung cancer.
Solomon B; Bunn PA
Cancer Invest; 2007 Jun; 25(4):217-25. PubMed ID: 17612931
[TBL] [Abstract][Full Text] [Related]
30. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer.
Früh M; Rolland E; Pignon JP; Seymour L; Ding K; Tribodet H; Winton T; Le Chevalier T; Scagliotti GV; Douillard JY; Spiro S; Shepherd FA
J Clin Oncol; 2008 Jul; 26(21):3573-81. PubMed ID: 18640938
[TBL] [Abstract][Full Text] [Related]
31. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.
Keller SM; Adak S; Wagner H; Herskovic A; Komaki R; Brooks BJ; Perry MC; Livingston RB; Johnson DH
N Engl J Med; 2000 Oct; 343(17):1217-22. PubMed ID: 11071672
[TBL] [Abstract][Full Text] [Related]
32. Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial.
Wakelee HA; Schiller JH; Gandara DR
Clin Lung Cancer; 2006 Jul; 8(1):18-21. PubMed ID: 16870041
[TBL] [Abstract][Full Text] [Related]
33. Triplet chemotherapy combinations with new agents: is there a rationale?
Bunn PA
Semin Oncol; 1998 Aug; 25(4 Suppl 9):55-61. PubMed ID: 9728586
[TBL] [Abstract][Full Text] [Related]
34. Platinum-based chemotherapy in non-small cell lung cancer: the experience of the European Organization for the Research and Treatment of Cancer.
van Zandwijk N; Dalesio O
Semin Oncol; 1994 Jun; 21(3 Suppl 6):66-71. PubMed ID: 8052876
[TBL] [Abstract][Full Text] [Related]
35. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
Imaizumi M;
Lung Cancer; 2005 Jul; 49(1):85-94. PubMed ID: 15949594
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of the unresectable non small cell lung carcinoma].
Spásová I
Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
[TBL] [Abstract][Full Text] [Related]
37. Dose-individualized stereotactic body radiotherapy for T1-3N0 non-small cell lung cancer: long-term results and efficacy of adjuvant chemotherapy.
Chen Y; Guo W; Lu Y; Zou B
Radiother Oncol; 2008 Sep; 88(3):351-8. PubMed ID: 18722684
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.
BMJ; 1995 Oct; 311(7010):899-909. PubMed ID: 7580546
[TBL] [Abstract][Full Text] [Related]
39. A randomized trial of mitomycin/ifosfamide/cisplatin preoperative chemotherapy plus surgery versus surgery alone in stage IIIA non-small cell lung cancer.
Rosell R; Maestre J; Font A; Moreno I; Molina F; Milla A; Gómez-Codina J; Camps C
Semin Oncol; 1994 Jun; 21(3 Suppl 4):28-33. PubMed ID: 8209274
[TBL] [Abstract][Full Text] [Related]
40. The role of adjuvant chemotherapy for non-small cell lung cancer.
Gurubhagavatula S; Lynch TJ
Semin Respir Crit Care Med; 2005 Jun; 26(3):298-303. PubMed ID: 16052431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
